Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Acacia Pharma Group plc: Change in Directors' Interests

Acacia Pharma Group plc
Posted on: 20 Mar 18

Acacia Pharma Group plc
20 March 2018

Change in Directors' interests in the shares of Acacia Pharma Group plc ("Acacia Pharma" or the "Company")

This notification is made in accordance with the Company's obligations under the Market Abuse Regulation.

The following transactions have taken place in relation to the executive directors under the Company's share plans.

Performance Share Plan
On 19 March 2018, the following directors were granted conditional awards ("Awards") under the Acacia Pharma Group plc Performance Share Plan (the "Plan"). Julian Gilbert was granted an Award over 96,875 Ordinary Shares and Christine Soden was granted an Award over 75,000 ordinary shares of £0.02 pence each in the Company ("Ordinary Shares") in each case in the form of options with an exercise price of £0.02 per share

In each case the Awards were granted over Ordinary Shares equal to 100% of salary at the point of grant as allowed for in the Prospectus for the Initial Global Offering of the Company's shares dated 2 March 2018, calculated at 320p per share (being the market price of the shares at the time of the Offering). No consideration was paid for the grant of these Awards.

The Awards will normally vest on 18 March 2021, subject to the satisfaction of the applicable performance conditions being met over the period to 31 December 2020.

Notification and public disclosure of transactions by persons discharging managerial responsibilities.

Details of the person discharging managerial responsibilities / person closely associated 
a) NameJulian Gilbert
Reason for the notification 
a)

 
Position/statusCEO, Director
b) 

 
Initial notification /Amendment Initial Notification
3

 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a) 

 
Name 

 
Acacia Pharma Group plc
b) 

 
LEI  213800SLDKXWKT6E3381


 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
1

 
Description of the financial instrument, type of instrumentOrdinary Shares of £0.02
  
Identification codeGB00BYWF9Y76
  
  Nature of the transaction 

 
Grant of conditional awards under the Company's Performance Share Plan
 Price(s) and volume(s)     
  Price(s)Volume(s)Total 
  £096,875£0 
     
 Aggregated information  
  • Aggregated Volume
96,875
  • Price
£0
  
  Date of the transaction 

 
19 March 2018
 Place of the transaction  Outside a trading venue
         



 
Details of the person discharging managerial responsibilities / person closely associated 

 
a) 

 
Name 

 
Christine Soden


 
Reason for the notification 

 
a) 

 
Position/statusCFO, Director
b) 

 
Initial notification /AmendmentInitial Notification


 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 

 
a) 

 
Name 

 
Acacia Pharma Group plc
b) 

 
LEI 

 
213800SLDKXWKT6E3381


 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 

 
1.

 
Description of the financial instrument, type of instrument Ordinary Shares of £0.02
 

Identification code
 

GB00BYWF9Y76
  
  Nature of the transaction 

 
Grant of conditional awards under the Company's Performance Share Plan
 Price(s) and volume(s)     
  Price(s)Volume(s)Total 
  £075,000£0 
     
 Aggregated information  
  • Aggregated volume
75,000
  • Price
£0
  
  
 Date of the transaction 19 March 2018
  Place of the transaction 

 
Outside a trading venue

Contacts

Acacia Pharma Group plc
Christine Soden, CFO
+44 1223 875130
IR@acaciapharma.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Acacia Pharma Group plc via GlobeNewswire
HUG#2177767
GlobeNewswire
globenewswire.com

Last updated on: 21/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.